Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.34 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346646 | 0.98 | ALDH1A1 (0.41) | HPGDALDH1A1HTTMMP1MMP2 | |
| SCHEMBL7299020 | 0.83 | CYP1A2 (0.46) | HPGDALDH1A1NPC1 | |
| SCHEMBL7303416 | 0.81 | CA2 (0.42) | HPGDALDH1A1MEN1KMT2A | |
| SCHEMBL7305057 | 0.81 | DPP4 (0.40) | HPGDALDH1A1DPP7DPP4 | |
| SCHEMBL7299462 | 0.81 | SMN1; SMN2 (0.47) | HPGDALDH1A1HTTGAAMEN1 | |
| SCHEMBL5559398 | 0.80 | HPGD (0.39) | HPGDALDH1A1HTTMMP1MMP2 | |
| SCHEMBL27651069 | 0.78 | ALDH1A1 (0.40) | HPGDALDH1A1HTTMMP1MMP2 | |
| SCHEMBL1106510 | 0.75 | CHRNB2 (0.46) | HPGDALDH1A1HTTMMP1MMP2 | |
| SCHEMBL25447805 | 0.73 | ALDH1A1 (0.48) | HPGDALDH1A1HTTMMP1MMP2 | |
| SCHEMBL21455835 | 0.73 | ALDH1A1 (0.48) | HPGDALDH1A1HTTMMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042864-A2 | PYRAZOLE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-02-12 | — | — | US | disclosed |
| US-6008228-A | COMPRISING A MIXTURE OF CARRIER MONOGLYCERIDES OF MEDIUM CHAIN-FATTY ACIDS | HOFFMAN-LA ROCHE INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042864-A2 | PYRAZOLE COMPOUNDS | CNR2, CNR1, GPR18 | HPGD 1493/4885ALDH1A1 1456/4885HTT 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.